0001104659-24-031578.txt : 20240306
0001104659-24-031578.hdr.sgml : 20240306
20240306182030
ACCESSION NUMBER: 0001104659-24-031578
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240304
FILED AS OF DATE: 20240306
DATE AS OF CHANGE: 20240306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRAF FINCKENSTEIN FRIEDRICH
CENTRAL INDEX KEY: 0001782981
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36860
FILM NUMBER: 24727496
MAIL ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001425205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 753254381
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD
STREET 2: 4TH FLOOR
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 6502607120
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD
STREET 2: 4TH FLOOR
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: Lion Biotechnologies, Inc.
DATE OF NAME CHANGE: 20131015
FORMER COMPANY:
FORMER CONFORMED NAME: Genesis Biopharma, Inc
DATE OF NAME CHANGE: 20100319
FORMER COMPANY:
FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP
DATE OF NAME CHANGE: 20080128
4
1
tm248073-3_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-03-04
0
0001425205
IOVANCE BIOTHERAPEUTICS, INC.
IOVA
0001782981
GRAF FINCKENSTEIN FRIEDRICH
C/O IOVANCE BIOTHERAPEUTICS, INC.
825 INDUSTRIAL ROAD, 4TH FLOOR
SAN CARLOS
CA
94070
0
1
0
0
Chief Medical Officer
0
Common Stock
2024-03-04
4
M
0
15623
0
A
49230
D
Common Stock
2024-03-04
4
F
0
8053
16.96
D
41177
D
Restricted Stock Units
2024-03-04
4
M
0
15623
0.00
D
Common stock
15623
31252
D
Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
Represents the common stock remaining after deducting the common stock withheld for taxes.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
The remaining RSUs will vest in equal quarterly installments.
Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.
/s/ Friedrich Graf Finckenstein
2024-03-06